Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01422915 · ClinicalTrials.gov registry record · Phase 2
Sorbent Therapy of the Cutaneous Porphyrias
A Phase 2 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT01422915 is a Phase 2 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 4 participants.
The verdict
NCT01422915, a Phase 2 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The investigators demonstrated that cholestyramine is an effective binding agent in vitro for porphyrins. A few isolated case reports of treatment of individuals with a cutaneous porphyria suggest that cholestyramine and colestipol effectively remove porphyrins. Hypothesis: orally administered colestipol will effectively reduce sun sensitivity and lower erythrocyte porphyrin concentrations in subjects with erythropoietic protoporphyria (EPP).
Interventions
- DRUG Colestipol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2011-05 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01422915
The ClinicalTrials.gov registry entry for NCT01422915 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Colestipol is the first listed.
NCT01422915 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01422915 about?
NCT01422915 is a clinical study titled "Sorbent Therapy of the Cutaneous Porphyrias". The investigators demonstrated that cholestyramine is an effective binding agent in vitro for porphyrins. A few isolated case reports of treatment of individuals with a cutaneous porphyria suggest that cholestyramine and colestipol effectively remove porphyrins. Hypothesis: orally administered coles...
What is the current status of trial NCT01422915?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2011-05. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01422915?
The interventions under investigation include: Colestipol (DRUG).
Who is sponsoring clinical trial NCT01422915?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.